Current treatments target the mitogen-activated protein kinase (MAPK) pathway, a key driver of melanoma growth. However, MAPK ...

The anti-melanogenesis effect of ligustroside derived from Ligustrum japonicum and its underlying mechanisms are explored.

My research focuses on developing rational combinations to overcome drug resistance in melanoma, lung and colorectal cancers. In particular, I explore pharmacological targeting and characterization of ...

Lutris Pharma, a clinical stage biopharmaceutical company focused on improving anti-cancer therapies by reducing cutaneous ...

Potentially best-in-class RAS-targeting franchise advancing with both ERAS-0015 and ERAS-4001 expected to enter the clinic in 2025 Ongoing Phase 3 SEACRAFT-2 registrational trial progressing well with ...

"The SEACRAFT-2 trial is progressing well, and with FDA Fast Track Designation (FTD) granted in NRASm melanoma, this combination has the potential to be first ... and commercializing therapies for ...